Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Video from Clinical Care Options (CCO): metabolic adaptations in obesity, value of sustained weight loss, and latest evidence for incretin-based therapies: semaglutide, tirzepatide, and mores
Clinical Care Options (CCO) presents Dr. George L. Bakris answering common questions about renoprotection strategies in CKD in T2D
Practicing Clinicians Exchange presents Fatima Cody Stanford, MD, MPH, MPA, MBA, answering commonly asked questions about the use of GLP-1 receptor agonist pharmacotherapy in obesity management.
Learn about renoprotection in diabetic kidney disease, CKD and CV outcomes; focus on emerging MR antagonists, from Clinical Care Options (CCO)